# Edap TMS SA > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Edap TMS SA). ## Overview EDAP TMS SA develops and commercializes minimally invasive medical systems, centered on its Focal One robotic high-intensity focused ultrasound (HIFU) platform for prostate care. The company also has legacy lithotripsy (ESWL) and medical device distribution activities, with operations and sales across the United States, Europe, and other international markets. ## Products & services • Focal One robotic HIFU systems • HIFU disposables and treatment-related services • Revenue-per-procedure (RPP) and operating lease models • Maintenance and installed-base support services • ESWL consumables, spare parts, and repair services • Medical device distribution services - **HIFU systems and treatment revenue** (65%) — Robotic HIFU systems, disposables, RPP arrangements, leases, and related services. - **HIFU maintenance and installed-base services** (7%) — Maintenance contracts and support services for installed Focal One systems. - **ESWL products and services** (8%) — Legacy lithotripsy consumables, spare parts, repair services, and residual system activity. - **Distribution services** (20%) — Third-party medical device distribution and related consumables, leasing, and services. - Focal One robotic HIFU systems - HIFU disposables and treatment-related services - Revenue-per-procedure (RPP) and operating lease models - Maintenance and installed-base support services - ESWL consumables, spare parts, and repair services - Medical device distribution services ## Customers EDAP sells primarily to hospitals, urology centers, and other healthcare providers that treat prostate and stone disease. Its HIFU business serves providers that want a robotic, minimally invasive therapy platform, while the RPP and lease models appeal to customers that prefer usage-based or lower upfront payment structures. The ESWL and distribution businesses serve installed-base users and healthcare buyers needing consumables, parts, and third-party devices. - **Hospitals and academic medical centers** (primary) — Buy Focal One systems and related services to add minimally invasive prostate treatment capability. - **Urology clinics and treatment centers** (primary) — Use RPP and lease arrangements to access HIFU technology with lower upfront capital needs. - **Installed-base ESWL customers** (secondary) — Purchase consumables, spare parts, and repairs for existing lithotripsy systems. - **Medical device distribution customers** (secondary) — Buy third-party devices and related consumables through the distribution channel. - Hospitals and surgical centers buying Focal One systems for prostate care - Urology practices using RPP or lease models to lower upfront spend - Installed-base customers needing HIFU maintenance and disposables - ESWL users purchasing electrodes, spare parts, and repair services - Healthcare distributors and providers buying third-party medical devices ## Geography EDAP has a multinational footprint, with meaningful activity in the United States and Europe and additional sales in other jurisdictions. The company uses different commercial models by region, including operating leases in the U.S. and RPP arrangements in Europe, which affects revenue timing and predictability. Its installed base and sales mix also create exposure to local reimbursement, regulatory, and adoption patterns in each market. - United States is a key market for Focal One system placements - Europe uses an RPP model for HIFU revenue generation - Other jurisdictions support additional system sales and services - Installed-base geography drives recurring maintenance and consumables demand - Regional commercial models affect revenue timing and predictability ## Strategy EDAP’s strategy is centered on expanding its proprietary HIFU franchise and reducing reliance on legacy ESWL and distribution activities. The company is building installed base, treatment-driven revenue, and recurring service streams while continuing to invest in commercialization and product development. This mix is intended to strengthen the long-term profile of the business around a differentiated medical technology platform. - **Expand HIFU commercialization** (short-term) — HIFU is the core proprietary platform and the main driver of future growth. - **Build recurring revenue streams** (medium-term) — RPP, leases, disposables, and maintenance reduce dependence on one-time equipment sales. - **Reduce reliance on legacy businesses** (medium-term) — ESWL and distribution are lower-priority activities and less central to the company’s platform strategy. - Expand Focal One adoption in the United States and other markets - Grow treatment-driven revenue through RPP, leases, and disposables - Increase installed base to support recurring maintenance revenue - De-emphasize legacy ESWL and distribution activities over time - Invest in sales, marketing, and R&D for new product development ## Risks EDAP depends on adoption of a specialized medical technology, so demand can be affected by hospital capital budgets, clinical acceptance, and reimbursement dynamics. The business also faces execution risk from its mix of equipment sales, leases, RPP contracts, and recurring service revenue, plus exposure to foreign exchange, tariffs, and regulatory requirements across markets. - **Dependence on HIFU adoption** [high] — The growth strategy relies on hospitals and clinics adopting Focal One and treatment workflows. - **Revenue timing from leases and RPP contracts** [medium] — Operating leases and revenue-per-procedure models spread revenue over time and can create quarter-to-quarter volatility. - **Legacy business decline** [medium] — ESWL system sales have ended and distribution agreements have been terminated, reducing legacy revenue streams. - **Foreign exchange and tariff exposure** [medium] — The company operates internationally and has disclosed tariff impact and euro-dollar sensitivity. - **Financing and dilution risk** [high] — Commercialization and R&D needs may require additional capital if operating cash generation is insufficient. - HIFU adoption risk if hospitals delay purchases or clinical uptake is slower - Revenue mix can shift with equipment sales, leases, and RPP timing - Legacy ESWL and distribution declines can offset HIFU growth - Tariffs, inflation, and FX can pressure costs and reported results - Additional financing may be needed to support commercialization and R&D ## Accounting A key accounting issue is revenue recognition across multiple models, including point-in-time equipment sales, over-time lease and RPP arrangements, and service revenue. The company also has judgment-heavy fair value accounting for EIB warrants and loan-related items, plus foreign currency translation effects that can move reported results. Because the business has recurring service revenue and installed-base activity, quarter-to-quarter comparability can be affected by timing of system placements, procedures, and maintenance work. - **Revenue recognition by business model** — Can shift revenue between quarters and change gross margin mix - **Fair value of warrants and debt-related instruments** — Can create volatility in non-operating income or expense - **Foreign currency translation and transaction effects** — Can materially affect reported earnings and cash balances - **Lease accounting and installed-base arrangements** — Influences balance sheet structure and recurring revenue profile - Revenue recognition differs across system sales, leases, RPP, and services - Fair value changes in EIB warrants can affect non-operating results - Loan amortization and interest expense affect financial expense - Foreign currency movements can create gains or losses in reported earnings - Quarterly revenue can vary with system placements and treatment activity --- *Last updated: 2026-06-16T22:52:12.731493+00:00*